Skip to main content
Livermore
Livermore
ZHEN

Captrust Financial Advisors

SEC CIK
0001512024
Latest filing
Aug 13, 2026

HALO holding history

Halozyme Therapeutics, Inc. in every 13F filed by Captrust Financial Advisors, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

HALO overviewAll 13F holders of HALOFull Q2 2026 holdings

Shares (Q2 2026)
125,946
Value
$9.86M
% of portfolio
<0.1%
Quarters held
19
Since Q1 2021
Holdings of HALO by Captrust Financial Advisors, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026125,946$9.86M<0.1%+4,858+4.0%AddedHolders
Q1 2026121,088$7.83M<0.1%+64,502+114.0%AddedHolders
Q4 202556,586$3.81M<0.1%+8,398+17.4%AddedHolders
Q3 202548,188$3.53M<0.1%−906−1.8%ReducedHolders
Q2 202549,094$2.55M<0.1%+14,519+42.0%AddedHolders
Q1 202534,575$2.21M<0.1%+4,713+15.8%AddedHolders
Q4 202429,862$1.43M<0.1%+5,829+24.3%AddedHolders
Q3 202424,033$1.38M<0.1%−2,330−8.8%ReducedHolders
Q2 202426,363$1.38M<0.1%−382−1.4%ReducedHolders
Q1 202426,745$1.09M<0.1%−711−2.6%ReducedHolders
Q4 202327,456$1.01M<0.1%+1,053+4.0%AddedHolders
Q3 202326,403$1.01M<0.1%+26,403NewHolders
Q1 20230$00.0%−4,606−100.0%Sold outHolders
Q4 20224,606$262.1K<0.1%+4,606NewHolders
Q3 20220$00.0%−3,902−100.0%Sold outHolders
Q2 20223,902$172.0K<0.1%+528+15.6%AddedHolders
Q1 20223,374$135.0K<0.1%+127+3.9%AddedHolders
Q4 20213,247$131.0K<0.1%+349+12.0%AddedHolders
Q3 20212,898$118.0K<0.1%+313+12.1%AddedHolders
Q2 20212,585$117.0K<0.1%−3−0.1%ReducedHolders
Q1 20212,588$108.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.